SCHEMBL2917415

SCHEMBL2917415

COCCCN1CCOc2ccc(CO[C@H]3CN[C@@H](CC(C)C(=O)NCC4CCCO4)C[C@@H]3c3ccc(OC)cc3)cc21

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.36
KMT2A Q03164 3/20 0.36
HPGD P15428 7/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
REN P00797 1/20 0.35
HTT P42858 4/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 4/20 0.35
KDM4E B2RXH2 4/20 0.34
CASP1 P29466 3/20 0.34
CASP7 P55210 3/20 0.34
GAA P10253 3/20 0.34
TSHR P16473 2/20 0.34
RAB9A P51151 2/20 0.34
RECQL P46063 1/20 0.34
NPC1 O15118 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917412 1.00 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL13435439 1.00 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL3465047 0.89 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL3465045 0.89 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL2925282 0.89 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDSMN1; SMN2L3MBTL1
SCHEMBL2924426 0.87 REN (0.35) ALDH1A1RENRORC
SCHEMBL2924429 0.87 REN (0.35) ALDH1A1RENRORC
SCHEMBL13435437 0.87 REN (0.35) ALDH1A1RENRORC
SCHEMBL2923919 0.87 REN (0.34) ALDH1A1KMT2ARENHTTLMNA
SCHEMBL2923921 0.87 REN (0.34) ALDH1A1KMT2ARENHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863803-B1 SUBSTITUTED PIPERIDINES NOVARTIS AG (CH) 2010-09-01 EP disclosed
US-7687495-B2 Substituted piperidines SPEEDEL EXPERIMENTA AG (CH) 2010-03-30 US disclosed
US-20100029628-A1 2,4,5-Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2010-02-04 US disclosed
EP-1958634-A2 Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease Speedel Experimenta AG (CH) 2008-08-20 EP disclosed
US-20080171748-A1 Substituted piperidines NOVARTIS AG (CH) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029628-A1 2,4,5-Substituted Piperidines as Renin Inhibitors REN, AGT, AGTR1 ALDH1A1 435/4885KMT2A 2879/4885HPGD 2099/4885
US-20080171748-A1 Substituted piperidines REN, ACE, AGTR2 ALDH1A1 222/4885KMT2A 2739/4885HPGD 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.